Table 2.
Treatment response outcomes: terlipressin vs midodrine plus octreotide
| Variable description | CBPS adjusted | Unadjusted | ||||||
| Midodrine and octreotide (N = 55) | Terlipressin (N = 89)a | Mean difference (95% CI) | P value | Midodrine and octreotide (N = 55) | Terlipressin (N = 159) | Mean difference (95% CI) | P value | |
| HRS reversal, % | 20.00 | 52.35 | 32.35 (17.40 to 47.30) | <0.0001 | 20.00 | 44.03 | 24.03 (10.80 to 37.25) | 0.0004 |
| Complete response, % | 14.55 | 48.19 | 33.65 (19.52 to 47.77) | <0.0001 | 14.55 | 40.88 | 26.34 (14.16 to 38.51) | <0.0001 |
| Complete or partial response, % | 23.64 | 54.55 | 30.91 (15.48 to 46.34) | 0.0001 | 23.64 | 53.46 | 29.82 (16.04 to 43.61) | <0.0001 |
| Change in renal function (SCr) from baseline, mg/dL, mean (SD) | 0.22 (1.36) | −0.70 (0.94) | −0.92 (−1.31 to −0.53) | <0.0001 | 0.22 (1.36) | −0.82 (1.09) | −1.04 (−1.44 to −0.64) | <0.0001 |
| Percent improvement in renal function (SCr) from baseline, mean (SD) | −13.42 (57.70) | 25.85 (35.21) | 39.27 (23.04 to 55.51) | <0.0001 | −13.42 (57.70) | 26.14 (32.94) | 39.57 (23.45 to 55.68) | <0.0001 |
CBPS, covariate balancing propensity scoring; CI, confidence interval; HRS, hepatorenal syndrome; SCr, serum creatinine.
a
N = 89 is the effective sample size for the terlipressin cohort after CBPS reweighting.